|
|
|
|
|
|
|
|
|
|
|
|
|
13.07.26 - 08:06
|
Sofinnova Partners Appoints David Evans as Partner (Business Wire)
|
|
|
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner:
Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capital
Over 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing
PARIS--(BUSINESS WIRE)--Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before...
|
|
|
09.07.26 - 13:03
|
Three New Independent Members Join Orano Med′s Governing Board (Business Wire)
|
|
|
VILLEJUIF, France--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, announces the appointment of Caroline Germa, Jean-Pierre Bizzari and Philippe Archinard as independent members of the Governing Board dedicated to the company's biotech activities. They will work alongside Fabrice Chouraqui, a member of the Governing Board since 2022, whose mandate continues.
With deep expertise spanning oncology, clinical development, biotechnology, innovation and corporate governance at leading global healthcare companies, the three new members further strengthen the Board's ability to support Orano Med's development.
With more than 20 years of experience in the pharmaceutical and biotech industries, Caroline Germa has deep expertise in oncology. She is currently Chief Medical Officer of Triana Biosciences and a member of Transcenta's Scientific Advisory Board. Caroline previously held senior leadership roles in oncology clinical development at AstraZeneca, Bristol Myers ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.06.26 - 16:54
|
66 With $1.3 Million. Here Are 3 Hidden Gems to Target (24/7 Wall St.)
|
|
|
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target...
|
|
|
29.06.26 - 14:06
|
Establishment Labs® Appoints Taylor Harris to Board of Directors (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--$ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors.
Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He currently serves on the board of directors of Procept BioRobotics and previously served as a director of Omada Health and Endologix. Most recently, he served as Chief Executive Officer of Cutera, Inc.
Prior to Cutera, Mr. Harris served as Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. Earlier in his career, he served as Chief Financial Officer of Zeltiq Aesthetics through its acquisition by Allergan and as C...
|
|
|
|
|
|
|
|
|
18.06.26 - 13:00
|
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 (Business Wire)
|
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET.
Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call.
A replay of the webcast will be available here approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and fo...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
